



CANCER PREVENTION &
RESEARCH INSTITUTE OF TEXAS


Commercialization Slate
First Cycle FY2012

Company Commercialization Awards

Guiding Principles

- ▶ **Impact on Patient Care**
 - ▶ **Impact on Economic Development in Texas**
 - ▶ **Return on Investment for Texas**
- 

Three-Step Review Process

- ▶ **Commercialization Review**
 - ▶ **Scientific Review**
 - ▶ **Continued Due Diligence**
- 

Milestone-Driven, Tranched-Funding Model

- ▶ Milestones are defined with input from commercialization reviewers, scientific reviewers, and due diligence consultants
- ▶ Milestones are built into the contract between CPRIT and the award recipient with funding tied to the accomplishment of agreed milestones.
- ▶ Release of tranched funding depends on achievement of milestones

Company Commercialization Award Slate

Amount: \$23,408,151

Application ID	Program Director	Title	Entity	Requested Award*
CC121020	Kim, Jason	Novel targeted biologics, Engineered Toxin Bodies (ETB), as cancer therapeutics	Molecular Templates, Inc.	\$10,600,000.00
CC121004	Holtz, Richard	Biobetter Cancer Monoclonal Antibody Program	Caliber Biotherapeutics, a wholly owned Subsidiary of G-Con LLC	\$12,808,151.00

***Subject to contract negotiations**

Molecular Templates:

Location:

Georgetown, TX

Total amount requested:

\$10,600,000

The idea: *Molecular Templates has developed a new technology for creating cancer drugs that appears to have advantages over existing technologies.*

Its lead drug is specifically designed to destroy Non-Hodgkin Lymphoma (NHL) cells and has shown promising results in early laboratory testing. There are over 65,000 cases of NHL diagnosed in the US each year. Despite advances in treatment, most patients still relapse; it is estimated that more than 20,000 patients a year will die from the disease in the US alone. Molecular Templates seeks CPRIT funding to advance its lead drug into human clinical testing.

Molecular Templates: Tranche Funding

- ▶ **Total Requested Funding for Molecular Templates :
\$10.6 million**
- ▶ **Year One budget is \$3.15 million**
- ▶ **Specific Tasks to be preformed:**
 - ❖ **Complete the toxicological and pharmacological profile of the lead drug**
 - ❖ **Establish a safe initial dose for first-in-human exposure**
 - ❖ **Complete all the required IND-enabling preclinical studies and produce GMP material for first clinical study**

Caliber Biopharmaceuticals:

Location: Bryan/College Station, TX
Total amount requested: \$12,808,151

The idea: *Caliber proposes to develop a “biobetter” Rituxan - a monoclonal antibody therapy that has dramatically changed the outlook for patients with Non-Hodgkin Lymphoma and chronic lymphocytic leukemia.*

The Rituxan biobetter, produced in hydroponic plants, will have enhanced ability to kill cancer cells, but impose no additional risks or side effects to patients. Because of Caliber’s unique plant-based biomanufacturing platform, the biobetter will be substantially less expensive, reducing costs by at least one third. At the end of this project Caliber will be positioned to develop biobetter forms of other cancer therapies, such as Herceptin and Avastin.

Caliber Biopharmaceuticals: Tranche Funding

- ▶ Total Requested Funding for Caliber: \$12.8 million
- ▶ Tranche 1 (18 months) budget: \$4.4 million
- ▶ Specific Tasks to be performed:
 - ❖ Develop a panel of biobetter Rituximab candidate molecules
 - ❖ Implement and validate specific assays for screening of candidate Rituxan biobetters
 - ❖ Develop a detailed product development plan
 - ❖ Demonstrate manufacturing proof of concept at pilot scale
 - ❖ Establish Scientific and Clinical Advisory Board